Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether intralesional triamcinolone changes maximal mouth opening (interincisal distance) compared with intralesional salvianolic acid B (very low certainty).
1 finding from 1 review
Physician Global Assessment (clinical signs, complete response) · People with erosive oral lichen planus
Fluocinonide in adhesive base showed no clear difference in physician Global Assessment (clinical signs, complete response) compared with placebo; GRADE not reported.
1 finding from 1 review
Partial response (>33% improvement) · People with erosive oral lichen planus
Fluocinonide in adhesive base showed no clear difference in partial response (>33% improvement) compared with placebo; GRADE not reported.
1 finding from 1 review
Side effects · People with erosive oral lichen planus
1 finding from 1 review
Adverse effects · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide showed no clear difference in adverse effects compared with topical pimecrolimus; GRADE not reported.
1 finding from 1 review
Adverse effects · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide may leads to lower adverse effects compared with topical tacrolimus (low certainty).
1 finding from 1 review
Pain (mean score) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide may leads to lower pain (mean score) compared with topical curcumin (low certainty).
1 finding from 1 review
Pain (mean score) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide showed no clear difference in pain (mean score) compared with intralesional BCG-polysaccharide nucleic acid (BCG-PSN); GRADE not reported.
1 finding from 1 review
Clinical score · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide may leads to higher clinical score compared with photodynamic therapy (low certainty).
1 finding from 1 review
Clinical resolution · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
It is very uncertain whether topical triamcinolone acetonide changes clinical resolution compared with topical tacrolimus (very low certainty).
1 finding from 1 review
Adverse effects · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide led to lower adverse effects compared with topical ciclosporin; GRADE not reported.
1 finding from 1 review
Pain (mean score) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide showed no clear difference in pain (mean score) compared with hyaluronic acid gel; GRADE not reported.
1 finding from 1 review
Pain (mean score, split-mouth) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
It is very uncertain whether topical triamcinolone acetonide changes pain (mean score, split-mouth) compared with cryotherapy (very low certainty).
1 finding from 1 review
Pain resolution · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
The review found no eligible studies for this question.
1 finding from 1 review
Pain (mean VAS score) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide showed no clear difference in pain (mean VAS score) compared with topical ciclosporin; GRADE not reported.
1 finding from 1 review
Adverse events (split-mouth) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide led to lower adverse events (split-mouth) compared with cryotherapy; GRADE not reported.
1 finding from 1 review
Pain (mean VAS score) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide showed no clear difference in pain (mean VAS score) compared with topical pimecrolimus; GRADE not reported.
1 finding from 1 review
Pain (mean score) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
It is very uncertain whether topical triamcinolone acetonide changes pain (mean score) compared with photodynamic therapy (very low certainty).
1 finding from 1 review
Physician Global Assessment (Thongprasom score) · People with erosive oral lichen planus
0.1% triamcinolone acetonide in orabase showed no clear difference in physician Global Assessment (Thongprasom score) compared with ciclosporin solution; GRADE not reported.
1 finding from 1 review
Pain reduction (VAS 0-100) · People with erosive oral lichen planus
0.1% triamcinolone acetonide in orabase led to higher pain reduction (VAS 0-100) compared with ciclosporin solution; GRADE not reported.
1 finding from 1 review